gp-6

GP-82996 (CINK4) is a pharmacological inhibitor specifically targeting CDK4 6, exhibiting IC50 values of 1.5 μM for CDK4 cyclin D1, 5.6 μM for CDK6 cyclin D1, and 25 μM for Cdk5 p35. It effectively induces apoptosis in U2OS cancer cells, positioning it as a potential investigational tool in cancer research [1] [2].

Anticancer Agent 108 (Compound 3.10) serves as a potent P-gp inhibitor exhibiting considerable antitumor properties while maintaining reduced toxicity to both normal and pseudonormal cells; it also demonstrated no acute toxic effects on C57BL/6 mice [1].

PF-06273340 is an effective, Selective, and Peripherally Restricted Pan-Trk inhibitor (IC50: Trk-A = 6 nM; Trk-B = 4 nM; Trk-C = 3 nM). PF-06273340 has low metabolic turnover in HLM and hHep is a good substrate for efflux transporters P-gp (ER = 35.7) and BCRP (ER = 4.0) and has moderate passive permeability (RRCK Papp = 5.4 × 10 6 cm s 1).

1. Isosinensetin (6-Demethoxynobiletin) shows antioxidant and HIV-1 protease inhibiting activities.

2,5,7,8,9,14-Hexaacetoxy-3-benzoyloxy-15-hydroxyjatropha-6(17),11E-diene (Jatrophane 2 ) exhibits significant antifeedant activity against a generalist plant-feeding insect, the cotton bollworm (Helicoverpa armigera). Jatrophane 2 also demonstrates the mo

Gp100 (25-33), human TFA is a 25-33 amino acid fragment of human melanoma antigen.Gp100 (25-33), human TFA is a 9-amino acid (AA) epitopes restricted by h-2db and recognized by T cells.